NIKKEI 225
38,356.06 +176.60 (+0.46%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
77.96 -1.16 (-1.47%) GOLD FUTURES
2,365.00 +22.00 (+0.94%) DOW
39,483.05 +51.54 (+0.13%) Bitcoin GBP
48,711.19 -1,041.78 (-2.09%)
Trinity Biotech plc (TRIB)
| Previous close | 1.5800 |
| Open | 1.5700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.4900 - 1.6250 |
| 52-week range | 1.4900 - 5.5000 |
| Volume | |
| Avg. volume | 20,386 |
| Market cap | 14.389M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.8000 |
| Earnings date | 04 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 Jun 2015 |
| 1y target est | N/A |
GlobeNewswireTrinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales
DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million. The Company has successfully scaled up production to meet the increased demand for its rapid HIV tests. A
Globe NewswireTrinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM s
Insider MonkeyTrinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript
Trinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript April 4, 202 Trinity Biotech plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings! Welcome to the Trinity Biotech’s Fourth Quarter and Full Year 2023 Earnings Conference Call. At this […]
